Mark C. Schneyer serves as the Executive Vice President and Chief Financial Officer at ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on developing innovative medicines to address unmet medical needs in central nervous system disorders. In his role, Schneyer is responsible for overseeing the company's financial strategy, accounting, and investor relations, playing a crucial role in guiding ACADIA's growth and financial health. Prior to joining ACADIA, Schneyer held several high-level financial positions at other notable biopharmaceutical companies. He was the Senior Vice President and Chief Financial Officer at Hyperion Therapeutics, where he played a key role in the company's successful IPO and subsequent sale to Horizon Pharma. Before Hyperion, Schneyer served as Vice President of Finance at InterMune, contributing to the company's financial strategy during a period of significant growth. His extensive experience in the biopharmaceutical industry, coupled with his strategic financial acumen, has been instrumental in driving ACADIA's financial performance and positioning the company for future success. Schneyer's achievements in the field have been recognized through various awards and acknowledgments. His leadership at ACADIA has been pivotal in navigating the company through complex financial landscapes, ensuring sustainable growth and profitability. Under his guidance, ACADIA has continued to advance its mission of bringing innovative treatments to patients with serious central nervous system disorders, solidifying its position as a leader in the biopharmaceutical industry.